This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval
Grail's Galleri blood test screens for 50 types of cancer from a single blood draw, but its path to wider insurance coverage depends on regulatory approval. A major study did not demonstrate that the test can reliably detect later-stage cancers, raising questions for Medicare and other payers about whether they will reimburse it.
Why It Matters
Medicare and private insurers typically base coverage decisions in part on FDA approval and evidence of clinical benefit; uncertainty about the test's ability to find advanced cancers could limit reimbursement and patient access. How payers respond will affect whether the test becomes broadly available beyond direct-to-consumer or self-pay markets.
Key Facts
- Test: Grail's Galleri
- What it screens for: 50 cancers
- Sample type: blood draw
- Regulatory hinge for coverage: FDA approval
- Study result: A major study failed to prove detection of later-stage cancers
Grail markets the Galleri test as a multi-cancer early detection tool that analyzes a blood sample to screen for 50 different cancers. The company has positioned the test as a potentially broad screening option, but wider adoption by patients will depend heavily on whether public and private insurers agree to cover it.
Coverage decisions by payers such as Medicare often hinge on whether a test has secured FDA approval and on the strength of clinical evidence showing benefit. In this case, a major study of Galleri did not demonstrate that the test reliably detected later-stage cancers, a finding that complicates the evidence base insurers use when evaluating reimbursement policies.
Without clear proof that Galleri detects advanced cancers, payers may be reluctant to extend coverage beyond limited or conditional scenarios. That could leave the test available primarily through out-of-pocket payment or in contexts where institutions or clinicians choose to offer it despite uncertain reimbursement.
The test's ultimate availability and use will therefore depend not only on future regulatory decisions but also on how insurers interpret existing study results and whether additional data addressing gaps in performance — especially for later-stage disease — becomes available.
Keep Reading
If Amazon doesn’t know how to eliminate carbon emissions, then who does?
Inflation could cost Republicans the Senate — this chart shows how
Trump’s China rivalry and “AI race” delusion may endanger US, experts say
